Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Rate and characteristics of infection after transrectal prostate biopsy : a retrospective observational study

Forsvall, Andreas LU orcid ; Jönsson, Hannah ; Wagenius, Magnus LU ; Bratt, Ola LU and Linder, Adam LU (2021) In Scandinavian Journal of Urology 55(4). p.317-323
Abstract

Objectives: The aim of this study was to assess the incidence of infection after transrectal prostate biopsy (TRbx). Secondary objectives were to describe infection characteristics, antibiotic resistance patterns, ICD-10 coding, and costs. Methods: TRbx carried out at the hospitals of Ängelholm and Helsingborg, Scania, Sweden, between October 2017 and March 2019, were identified based on the NOMESCO Classification of Surgical Procedures code for TRbx, TKE00. All patients received per oral antibiotic prophylaxis, usually 750 mg ciprofloxacin at biopsy. Other preventative measures were not used. Medical care within 30 days of the biopsy was evaluated through a manual retrospective medical chart review. Data on patient and infection... (More)

Objectives: The aim of this study was to assess the incidence of infection after transrectal prostate biopsy (TRbx). Secondary objectives were to describe infection characteristics, antibiotic resistance patterns, ICD-10 coding, and costs. Methods: TRbx carried out at the hospitals of Ängelholm and Helsingborg, Scania, Sweden, between October 2017 and March 2019, were identified based on the NOMESCO Classification of Surgical Procedures code for TRbx, TKE00. All patients received per oral antibiotic prophylaxis, usually 750 mg ciprofloxacin at biopsy. Other preventative measures were not used. Medical care within 30 days of the biopsy was evaluated through a manual retrospective medical chart review. Data on patient and infection characteristics were collected. The costs of infections causing hospitalization were estimated. Results: After 36 (5.4%) of 670 biopsies, the patient developed post-biopsy infection within 30 days after TRbx. Twenty-six patients (3.9%) required hospitalization for an average of 6 days, at an estimated direct cost of USD 9174 (EUR 8031) per patient. Nine patients (1.3%) had a complicated infection leading to intensive care, multiple hospitalizations or emergency department visits. The inpatient care episodes for the 26 hospitalized patients were categorized with 15 different ICD-codes. In 6 episodes no ICD-code related to infection was used. Conclusions: In this study, we found an infection rate of 5.4% after TRbx; 3.9% of the patients were hospitalized for a post-TRbx infection and 1.3% had complicated infections. A specific ICD code for post-TRbx infections would facilitate evaluation and monitoring of this common, costly, and sometimes serious complication.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
biopsy, infections, International Classification of Diseases, needle, Prostate cancer, sepsis, transrectal prostate biopsy
in
Scandinavian Journal of Urology
volume
55
issue
4
pages
7 pages
publisher
Taylor & Francis
external identifiers
  • pmid:34096449
  • scopus:85106242544
ISSN
2168-1805
DOI
10.1080/21681805.2021.1933169
language
English
LU publication?
yes
id
ec86caa7-4374-4161-a7ad-75bb94bf6536
date added to LUP
2022-02-04 15:55:50
date last changed
2024-07-03 16:58:03
@article{ec86caa7-4374-4161-a7ad-75bb94bf6536,
  abstract     = {{<p>Objectives: The aim of this study was to assess the incidence of infection after transrectal prostate biopsy (TRbx). Secondary objectives were to describe infection characteristics, antibiotic resistance patterns, ICD-10 coding, and costs. Methods: TRbx carried out at the hospitals of Ängelholm and Helsingborg, Scania, Sweden, between October 2017 and March 2019, were identified based on the NOMESCO Classification of Surgical Procedures code for TRbx, TKE00. All patients received per oral antibiotic prophylaxis, usually 750 mg ciprofloxacin at biopsy. Other preventative measures were not used. Medical care within 30 days of the biopsy was evaluated through a manual retrospective medical chart review. Data on patient and infection characteristics were collected. The costs of infections causing hospitalization were estimated. Results: After 36 (5.4%) of 670 biopsies, the patient developed post-biopsy infection within 30 days after TRbx. Twenty-six patients (3.9%) required hospitalization for an average of 6 days, at an estimated direct cost of USD 9174 (EUR 8031) per patient. Nine patients (1.3%) had a complicated infection leading to intensive care, multiple hospitalizations or emergency department visits. The inpatient care episodes for the 26 hospitalized patients were categorized with 15 different ICD-codes. In 6 episodes no ICD-code related to infection was used. Conclusions: In this study, we found an infection rate of 5.4% after TRbx; 3.9% of the patients were hospitalized for a post-TRbx infection and 1.3% had complicated infections. A specific ICD code for post-TRbx infections would facilitate evaluation and monitoring of this common, costly, and sometimes serious complication.</p>}},
  author       = {{Forsvall, Andreas and Jönsson, Hannah and Wagenius, Magnus and Bratt, Ola and Linder, Adam}},
  issn         = {{2168-1805}},
  keywords     = {{biopsy; infections; International Classification of Diseases; needle; Prostate cancer; sepsis; transrectal prostate biopsy}},
  language     = {{eng}},
  number       = {{4}},
  pages        = {{317--323}},
  publisher    = {{Taylor & Francis}},
  series       = {{Scandinavian Journal of Urology}},
  title        = {{Rate and characteristics of infection after transrectal prostate biopsy : a retrospective observational study}},
  url          = {{http://dx.doi.org/10.1080/21681805.2021.1933169}},
  doi          = {{10.1080/21681805.2021.1933169}},
  volume       = {{55}},
  year         = {{2021}},
}